Obulytix at the AMR Conference (Basel, March 3-4, 2026)

On March 3 & 4, 2026, Obulytix will participate in the AMR Conference in Basel, an international conference focused on emerging antimicrobials and diagnostics that aim to reshape the future of antimicrobial therapies.

Our CEO, Kristof Van Emelen, will join a panel of experts to discuss how new approaches in antimicrobial resistance innovation can overcome the limitations of conventional antibiotics.

We look forward to contributing to this dialogue, learning from diverse approaches, and collectively advancing the future of antimicrobial resistance innovation.

Rethinking antimicrobial resistance innovation

At Obulytix, we focus on Precision Lysin Therapeutics (PLTs), engineered biologics designed to selectively target specific bacterial pathogens while preserving beneficial microbiota.

This targeted approach enables more predictable outcomes and aligns with the growing need for sustainable, resistance-conscious therapies.

Precision Lysin Therapeutics as an innovative AMR strategy

During the AMR Conference, Kristof will share how Obulytix advances antimicrobial resistance innovation through its lysin platform, addressing challenges such as:

• Targeted activity against multidrug-resistant Gram-negative pathogens

• Lower risk of resistance development

• Scalable production of serum-stable biologics

Obulytix translates antimicrobial resistance innovation into solutions that are clinically relevant and industrially scalable.

Collaboration as a driver of antimicrobial resistance innovation

Obulytix is actively seeking strategic partnerships to advance the development of lysin-based therapeutics for indications driven by multidrug-resistant Gram-negative pathogens. Our scalable and precision-driven platform offers a compelling opportunity to address urgent unmet medical needs in infectious disease.

The AMR Conference provides a unique opportunity to exchange perspectives with researchers, biotech companies and industry leaders working on complementary solutions.

Guy Hermans (CSO), Dennis Grimon (Operations Lead), and Maria Fonseca (Portfolio Lead) will also be present at the conference engaging with potential scientific and strategic partners interested in learning more about our PLTs.

See you in Basel.

Obulytix team